CD7 UCAR-T cells

Developed for: T-cell leukemia · T-cell non-Hodgkin lymphoma
Investigated by: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Central South University · First Affiliated Hospital of Kunming Medical University · Fujian Medical University Union Hospital · Gracell Biotechnologies (Shanghai) Co., Ltd. · Nanfang Hospital, Southern Medical University
+7 more
· Second Affiliated Hospital of Xi'an Jiaotong University · Tang-Du Hospital · The Affiliated Hospital Of Guizhou Medical University · The First Affiliated Hospital of Anhui Medical University · The General Hospital of Western Theater Command · The Second Affiliated Hospital of Chongqing Medical University · Xinqiao Hospital of Chongqing

today NCT04264078 · Ph 0

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 0	NCT04264078	Mar 2021 → Jun 2022	T-cell leukemia, T-cell non-Hodgkin lymphoma	Xinqiao Hospital of Chongqing	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	CD7 UCAR-T cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04264078 ↗
Modality	Cell therapy	“anti-CD7 universal CAR-T cells” NCT04264078 ↗